Clinical trial
A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT07516093 is registered in ClinicalTrials.gov with Nurix Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lead sponsor
- Nurix Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 3, 2026
- Completion date
- August 31, 2033
- Enrollment
- 620 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma